Skip to content

Home
Company
Clinical Research
Technology
Partnerships
News
Contact

Home
Company
Clinical Research
Technology
Partnerships
News
Contact

Publications, Papers and Posters

INT230-6 Demonstrates Activity as Monotherapy and in Combination with Ipilimumab (IPI) Across a Broad Spectrum of Refractory Soft Tissue Sarcomas (STS) [Intensity IT-01; BMS#CA184-592]

June 3, 2022

Intratumoral INT230-6 Causes Tumor Necrosis and Promotes a Systemic Immune Response; Results from a Multi-center Phase 1/2 Study of Solid Tumors with and without Pembrolizumab (PEM) [Intensity IT-01; Merck KEYNOTE-A10]

June 3, 2022

Intratumoral (IT) INT230-6 Can Cause Tumor Necrosis in vivo: Preliminary Results of a Phase II Randomized Presurgical Window-of-Opportunity Study in Early Breast Cancers (the INVINCIBLE study) – PART I

June 3, 2022

Safety and Efficacy of INT230-6, a Potential First-in-Class Intratumoral Therapy, in Monotherapy and in Combination with Pembrolizumab: Results from the IT-01 Study [KEYNOTE-A10] in Subjects with Locally Advanced, Unresectable and Metastatic Breast Cancer

December 10, 2021

Survival and Immune Response Data from Intratumoral INT230-6 Alone (IT-01) and with Pembrolizumab [KEYNOTE-A10] in Subjects with Locally Advanced, Unresectable and Metastatic Solid Tumors

November 14, 2021

Intratumoral INT230-6 shows a favorable safety profile and early signs of efficacy in advanced soft tissue sarcoma with monotherapy and in combination with Ipilimumab [Intensity IT-01; BMS#CA184-592]

November 14, 2021

Safety and Efficacy from a Phase 1/2 Study of Intratumoral INT230-6 Alone or in Combination with Ipilimumab [Intensity# IT-01; BMS# CA184-592] in Adult Subjects with Metastatic Sarcomas (NCT 03058289)

November 12, 2021

Presented at the Connective Tissue Oncology Society (CTOS) 2021 Virtual Annual Meeting

A Phase 1/2 study of IntratumoralINT230-6 Alone (IT-01) or in Combination with Pembrolizumab [KEYNOTE-A10] in Adult Subjects with Locally Advanced, Unresectable and Metastatic Solid Tumors Refractory to Therapy

June 4, 2021

Early Results of Intratumoral INT230-6 Alone or in Combination with Ipilimumab in Subjects with Advanced Sarcomas

June 4, 2021

Poster: Intratumoral INT230-6 increases tumor T cell infiltration and results in durable benefit as monotherapy and in combination with pembrolizumab in refractory patients

October 26, 2020

Presented by Dr. El-Khoueiry at SITC 2020

« Previous Page1 Page2 Page3 Next »

Privacy Policy

Menu

Privacy Policy

© 2022 Intensity Therapeutics. All rights reserved.

Linkedin Twitter

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok